Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Telix Pharmaceuticals Limited before investing.

In this article, we go over a few key elements for understanding Telix Pharmaceuticals Limited’s stock price such as:

• Telix Pharmaceuticals Limited’s current stock price and volume
• Why Telix Pharmaceuticals Limited’s stock price changed recently
• Upgrades and downgrades for TLX from analysts
• TLX’s stock price momentum as measured by its relative strength

About Telix Pharmaceuticals Limited (TLX)

Before we jump into Telix Pharmaceuticals Limited’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Want to learn more about Telix Pharmaceuticals Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Telix Pharmaceuticals Limited.

Telix Pharmaceuticals Limited’s Stock Price as of Market Close

As of June 18, 2026, 4:00 PM, CST, Telix Pharmaceuticals Limited’s stock price was $10.090.

Telix Pharmaceuticals Limited is 0% from its previous closing price of $10.090.

During the last market session, Telix Pharmaceuticals Limited’s stock traded between $9.950 and $10.160. Currently, there are approximately 338.56 million shares outstanding for Telix Pharmaceuticals Limited.

Telix Pharmaceuticals Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Telix Pharmaceuticals Limited Stock Price History

Telix Pharmaceuticals Limited’s (TLX) price is currently up 7% so far this month.

During the month of June, Telix Pharmaceuticals Limited’s stock price has reached a high of $10.160 and a low of $8.690.

Over the last year, Telix Pharmaceuticals Limited has hit prices as high as $17.250 and as low as $6.280. Year to date, Telix Pharmaceuticals Limited’s stock is up 34.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Telix Pharmaceuticals Limited Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 18, 2026, there were analysts who downgraded Telix Pharmaceuticals Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Telix Pharmaceuticals Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Telix Pharmaceuticals Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Telix Pharmaceuticals Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Telix Pharmaceuticals Limited (TLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Telix Pharmaceuticals Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 18, 2026, Telix Pharmaceuticals Limited has a weighted four-quarter relative price strength of -10.20%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how Telix Pharmaceuticals Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Telix Pharmaceuticals Limited Stock Price: Bottom Line

As of June 18, 2026, Telix Pharmaceuticals Limited’s stock price is $10.090, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Telix Pharmaceuticals Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.